



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/634,663	08/05/2003	Sidney T. Smith	TR-5934	6356
29200	7590	05/31/2007		
BAXTER HEALTHCARE CORPORATION			EXAMINER	
1 BAXTER PARKWAY			BOWERS, NATHAN ANDREW	
DF2-2E			ART UNIT	PAPER NUMBER
DEERFIELD, IL 60015			1744	
			MAIL DATE	DELIVERY MODE
			05/31/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/634,663	SMITH ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Nathan A. Bowers	1744

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 27 March 2007.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-21 and 23-48 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-21 and 23-48 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All
  - b) Some \*
  - c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |                                                                                      |                                                                   |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date: _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date: _____                                                         | 6) <input type="checkbox"/> Other: _____                          |

**DETAILED ACTION**

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

- 1) Claims 1-21, 23-34 and 48-53 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smith (US 5935847) in view of Toner (US 6759245).

With respect to claims 1 and 48, Smith discloses a *closed* cell culture container (Figure 2:20) comprising a first flexible sidewall (Figure 2:22) connected to a portion of an opposing second flexible sidewall (Figure 2:24) along a peripheral seal to define a containment area (Figure 2:26). This is disclosed in column 6, lines 12-33. Column 2, lines 24-31 and column 3, line 59 to column 4, line 46 teach that the first and second sidewalls are constructed from flexible polymeric materials that permit cellular respiration. Column 5, lines 39-45 indicate that the sidewalls are constructed from ethylene vinyl acetate. A polystyrene layer (Figure 2:12) is provided to promote cell adhesion to the inside surface of the culture container. Smith, however, does not expressly state that a fibrin matrix layer is positioned on a portion of the interior surface of the first or second sidewalls of the cell culture container.

Toner discloses a cell culturing device (Figure 1) that includes a chamber divided by a gas permeable, liquid impermeable polymeric membrane (Figure 2:30). Cells (Figure 2:40) are seeded upon the membrane, and gases from an oxygenated liquid stream (Figure 2:20) are allowed to diffuse through the membrane in order to contact the cells. This is disclosed in column 3, lines 1-25 and column 7, line 10 to column 8, line 19. Column 9, lines 8-42 indicate that the membrane may be constructed from a variety of polymer compounds arranged in a single or multi-layered assembly. Column 11, lines 27-56 teach that the membrane (Figure 1:30) is coated with a fibrin matrix layer (Figure 1:41) to increase cell adhesion.

Smith and Toner are analogous art because they are from the same field of endeavor regarding cell culture containers.

At the time of the invention, it would have been obvious to include a fibrin matrix layer positioned on the interior surface of the polystyrene layer disclosed by Smith. In column 6, line

65 to column 7, line 19, Smith teaches that it is desirable to provide a culture vessel which includes sidewalls that are capable of accommodating adherent dependent cells. Toner teaches in column 11, lines 26-56 that fibrin, when applied to a polymer substrate, will enhance cell immobilization to the polymer substrate. In this way, Smith's invention would be improved through the addition of a fibrin matrix layer because the fibrin matrix would allow the cell culture container to better accommodate a wider range of adherent dependent cell types.

With respect to claims 2-4, Smith and Toner disclose the apparatus set forth in the 35 U.S.C. 103 rejection above. In addition, Smith teaches in column 4, lines 11-46 that the gas permeable material is either EVA, polyolefin, polyamide or styrene. The polymeric material of the first sidewall is a styrene and hydrocarbon multi-component polymer blend.

With respect to claims 5-11, 49 and 50, Smith and Toner disclose the apparatus set forth in the 35 U.S.C. 103 rejection above. In addition, Smith teaches that the gas permeable material is either a monolayer or a multilayer structure. Monolayer cell culture containers are well known in the art, and Figures 1 and 4 illustrate multilayer embodiments. A polystyrene layer (Figure 4:12) and a skin layer (Figure 4:18) are provided in addition to the substrate layer (Figure 4:14). Column 5, lines 7-18 teach that the skin layer and substrate layer are formed on the outer surface of the polystyrene layer, so that the inner surface of the polystyrene layer forms the interior surface of the culture chamber. The skin layer is formed from polyethylene copolymers and polypropylene copolymers. Column 4, lines 11-46 indicate that substrate layer is anywhere from 0-40% ethylene vinyl acetate copolymer. It is an intrinsic feature of the invention that the

composition of the substrate and polystyrene layers can be manipulated in order to achieve any desired polymer distribution.

The claimed weight ratios are simply result effective variables. In the absence of new or unexpected results, it would have been obvious to optimize the composition of the substrate and skin layers. This optimization could simply be accomplished by producing different compositions and testing their ability to be used in cell culturing. See *In re Boesch*, 617 F.2d 272, 205 USPQ 215 (CCPA 1980).

With respect to claims 12-21, 23-26 and 51-53, Smith and Toner disclose the apparatus set forth in the 35 U.S.C. 103 rejection above. In addition, Smith states in column 2, lines 24-31 that the polystyrene layer (1<sup>st</sup> layer) has a thickness within the range of 0.0001 inches to 0.001 inches. Column 4, lines 47-56 indicate that the substrate layer (2<sup>nd</sup> layer) has a thickness of 0.004 inches to 0.025 inches. Column 4, lines 11-46 teach that the second layer is a multi-component polymer blend that includes styrene and hydrocarbon copolymer. Figure 2 indicates that the gas permeable EVA material is used in the construction of both the first and second sidewalls. The nature of the invention regarding copolymer content and layer thickness has already been described.

With respect to claims 27-32, Smith and Toner disclose the apparatus set forth in the 35 U.S.C. 103 rejection above. In addition, Smith states in column 2, lines 39-51 that the culture container has a oxygen permeability of 9-15 Barrers, a carbon dioxide permeability of 40-80 Barrers, a nitrogen permeability of 10-100 Barrers and a water vapor transmission rate of less

Art Unit: 1744

than 20 (g mil/100 in<sup>2</sup>/day). Column 5, line 49 to column 6, line 8 indicates that the first and second sidewalls have a flexural modulus of 10,000-30,000 psi, and that the sidewalls are optically clear. The container is radiation sterilizable. Column 7, lines 39-44 indicate that at least one port (Figure 9:40) provides access to the containment area.

With respect to claims 34 and 35, Smith and Toner disclose the apparatus set forth in the 35 U.S.C. 103 rejection above. In addition, Smith states in column 6, line 66 to column 7, line 19 that the inside surfaces of the culture container can be modified in order to determine to what areas cells are allowed to adhere. Accordingly, it would have been obvious to apply the fibrin matrix disclosed by Toner to any part of the container surface that is desired to promote cell adhesion. This intrinsically could pertain to the entire inner surface of the container, or just specific regions of the inner surface. If the culture container is intended to facilitate the growth of adherent cell types, then it would be obvious to apply the fibrin matrix to the entire sidewall interior surface. If the culture container is intended to facilitate the growth of adherent and non-adherent cell types, then it would be obvious to apply the fibrin matrix to just a part of the sidewall interior surface.

2) Claims 36-46 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smith (US 5935847) in view of Toner (US 6759245) as applied to claim 1, and further in view of Delmotte (US 5989215).

With respect to claims 35-37, Smith and Toner disclose the invention set forth in the 35 U.S.C. 103 rejections above, however do not expressly disclose the nature of the fibrin matrix.

Delmotte discloses a method for forming a fibrin matrix that includes delivering a first solution of fibrinogen and factor XIII and a second solution of thrombin and calcium to a desired surface. This is disclosed in column 3, lines 31-44 and column 8, lines 3-15. In column 12, line 34 to column 13, line 20, Delmotte states that the amount of thrombin added to the fibrinogen solution is directly related to the pore size of the fibrin matrix product. Thrombin can be added in varying amounts in order to create a fibrin network characterized by pore diameters anywhere between 0.2-4 microns.

Smith, Toner and Delmotte are analogous art because they are from the same field of endeavor regarding cell culture systems.

At the time of the invention, it would have been obvious to form a fibrin matrix within the cell culture container disclosed by Smith and Toner by mixing a solution of fibrinogen with a solution of thrombin. In column 4, line 57 to column 5, line 16, Delmotte states that by separating fibrinogen and thrombin into two separate solutions, one is able to more easily manipulate the concentrations of fibrinogen and thrombin to effect change in the characteristics of the resultant fibrin film. In this way, the concentration of thrombin can be readily changed in order to create a fibrin matrix with a desired pore size.

With respect to claims 38-46, Smith, Toner and Delmotte disclose the apparatus set forth in the 35 U.S.C. 103 rejection above. In column 7, lines 29-32, Delmotte teaches that the components of the fibrinogen and thrombin are derived from human plasma. It would have been obvious to utilize recombinant components of fibrinogen and thrombin, as well. When the fibrin matrix is used in a bioreactor and not for treating a human being, it is less important to use

fibrinogen and thrombin attained from human blood plasma. Techniques for creating recombinant biomolecules are well known in the art.

With respect to claim 47, Smith, Toner and Delmotte disclose the apparatus set forth in claim 37 as set forth in the 35 U.S.C. 103 rejection above. In addition, Delmotte discloses in column 8, lines 3-29 that fibrin is made from a first solution containing 10-40 IU/ml of fibrinogen and factor XIII, and a second solution containing 3-10,000 IU/ml of thrombin and 45 micromoles/ml of calcium. Column 15, lines 1-15 disclose a method in which the fibrinogen and thrombin solutions are repeatedly applied to a surface in 0.3 ml increments. Column 18, lines 51-63 disclose a method in which 3.5 ml of the fibrinogen and thrombin solutions are mixed to form a fibrin matrix. The fibrinogen and thrombin solutions are incubated, and the formed fibrin matrix has a pore size of anywhere between 0.2-4 microns.

#### *Response to Arguments*

Applicant's arguments filed 27 March 2007 with respect to the 35 U.S.C. 103 rejections involving Smith, Toner, and Delmotte have been fully considered but they are not persuasive.

#### *Applicant's principle arguments are*

*(a) Toner teaches away from a container having flexible exterior sidewalls as recited in the claims. Toner's cartridge having rigid and gas permeable exterior sidewalls teaches away from cell culture containers having flexible and gas permeable exterior sidewalls. Additionally, Toner discloses a flow-through cell-culturing device, and therefore discloses an open system, not a closed system.*

In response to Applicant's arguments, please consider the following comments.

Smith discloses a cell culture container with flexible gas permeable sidewalls that is very similar to the cell culture container in the instant application. Smith clearly discloses that the container is *closed*. The only difference is the fact that the container in the Smith reference does not include a fibrin matrix layer. The Toner reference is combined with the Smith reference in order to show that it would have been obvious to improve the existing cell culture container by implementing a fibrin matrix layer. Toner indicates that fibrin, when applied to a polymer substrate, will enhance cell immobilization to the polymer substrate. In this way, Smith's invention would be improved through the addition of a fibrin matrix layer because the fibrin matrix would allow the cell culture container to better accommodate a wider range of adherent dependent cell types.

If, theoretically, Toner indicated that the use of fibrin coating layers is only applicable in flow-through culturing devices that comprise rigid and impermeable walls, then perhaps the combination of Smith with Toner would be inapplicable since Smith requires a closed culturing device comprising flexible and permeable walls. However, in no way does Toner indicate that the use of fibrin is contingent on the bioreactor wall type. There is simply no reason to believe that the fibrin layer of Toner would not work to effectively promote cell adhesion in the system of Smith. As detailed above, Toner provides clear and persuasive motivation that would lead one of ordinary skill in the art to add a fibrin layer to the culture system of Smith.

In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on

combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

***Conclusion***


**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nathan A. Bowers whose telephone number is (571) 272-8613. The examiner can normally be reached on Monday-Friday 8 AM to 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gladys Corcoran can be reached on (571) 272-1214. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



NAB



GLADYS J.P. CORCORAN  
SUPERVISORY PATENT EXAMINER